Medicare clarifies coverage for rare-disease treatment in nursing homes
H.R. 8528 — PI Post Acute Access Act · Filed by Adrian Smith (R-NE) · 4 cosponsors · Introduced Apr 27, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicare's skilled nursing facility (SNF) payment rules to explicitly cover intravenous immune globulin (IVIG) treatments and related services for patients with primary immunodeficiency disease, effective October 1, 2026. Currently, Medicare SNF coverage for IVIG is ambiguous or denied; this bill clarifies that IVIG and the nursing/infusion services needed to deliver it are covered benefits, allowing immunodeficiency patients to receive this critical treatment in SNFs rather than only in hospitals or outpatient clinics.
Why we flagged it
The bill is a straightforward technical amendment to Medicare's SNF benefit rules, adding a specific drug and related services to the covered-items list. It is not a new program, subsidy, or deregulation—it is a clarification of existing benefit scope.
What the text implies
- IVIG manufacturers (Grifols, CSL Behring, Takeda, Octapharma) may see increased volume and revenue if SNF-based IVIG delivery expands, though the bill does not mandate IVIG use—it only clarifies coverage.
- SNFs may need to invest in infusion infrastructure and staff training to deliver IVIG safely, creating upfront costs offset by Medicare reimbursement.
The full analysis lists 3 implications of this text.
Who stands to gain
intravenous immunoglobulin manufacturers; skilled nursing facilities; patients with primary immunodeficiency disease (reduced out-of-pocket costs)